康脂素藥業(yè)有限責任公司創(chuàng)業(yè)計劃書

1、康脂素藥業(yè)有限責任公司創(chuàng)業(yè)計劃書 二零零八年四月目錄第一章：執(zhí)行概要一、公司簡介···········································&#

2、183;·····································06二、市場描述···········

3、··················································

4、····················06三、公司管理····························

5、3;·················································

6、3;··08四、公司戰(zhàn)略規(guī)劃··············································

7、····························08五、場地及設(shè)施····················

8、83;·················································

9、83;······08六、投資與財務(wù)··········································

10、···································08第二章：康脂素新藥研究一、產(chǎn)品來源············

11、;··················································

12、;···················09二、原料來源·····························

13、83;·················································

14、83;·09三、新藥研究···············································&

15、#183;·································09 臨床前研究···············

16、;··················································

17、;··············10 劑量的選擇··································

18、83;············································27康脂素質(zhì)量標準起草說明···&#

19、183;·················································&#

20、183;······28產(chǎn)品生產(chǎn)工藝··········································

21、·································36產(chǎn)品包裝················

22、··················································

23、···············38品種規(guī)劃··································

24、···············································38第三章：生產(chǎn)質(zhì)量管理一、生產(chǎn)管理

25、··················································

26、·······························39二、生產(chǎn)要求·················

27、3;·················································

28、3;·············40三、廠房建設(shè)···································&#

29、183;·············································41四、成本控制···

30、··················································

31、····························41五、質(zhì)量管理····················

32、3;·················································

33、3;··········41六、產(chǎn)品研發(fā)······································&#

34、183;··········································42七、生產(chǎn)工藝流程·····

35、3;·················································

36、3;··················42八、設(shè)備管理······························&#

37、183;·················································&#

38、183;42九、物料管理················································

39、·································44第四章：公司管理一、公司概況··············&#

40、183;·················································&#

41、183;················45二、產(chǎn)品核心競爭力·······························

42、83;······································46三、公司遠景··········&

43、#183;·················································&

44、#183;····················47四、公司組織結(jié)構(gòu)及各部門職能··························

45、83;·························47五、公司的發(fā)展戰(zhàn)略······················

46、3;···············································49第五章：市場營銷分析一、市場

47、概述·················································

48、3;·······························52二、市場需求分析·················

49、··················································

50、·······53三、消費對象和消費者購買特點········································&#

51、183;············56四、企業(yè)綜合分析···································

52、3;······································57第六章：市場營銷一、目標市場·········

53、··················································

54、······················58二、市場定位··························

55、3;·················································

56、3;····58三、營銷組合策略············································

57、······························59四、促銷策略··················

58、3;·················································

59、3;············61第七章 財務(wù)規(guī)劃與投資分析一、資本結(jié)構(gòu)與規(guī)模·································

60、3;····································65二、資金來源及運用············

61、;··················································

62、;········66三、投資的可行性分析········································

63、;···························66四、投資凈現(xiàn)值和報酬率····················

64、3;···········································67五、項目敏感性分析·····

65、;··················································

66、;················69六、項目經(jīng)營安全性分析·······························

67、3;································70七、投資回報················&#

68、183;·················································&#

69、183;···············70第八章 財務(wù)分析一、主要財務(wù)假設(shè)·······························&#

70、183;··········································71二、銷售預(yù)測······

71、··················································

72、·························71三、成本費用核算·······················&#

73、183;·················································&#

74、183;72四、利潤表················································&

75、#183;····································73五、資產(chǎn)負債表···········

76、3;·················································

77、3;················74六、現(xiàn)金流量表································&

78、#183;·············································75七、財務(wù)指標分析··

79、83;·················································

80、83;·····················76八、風險及其評價···························

81、;···············································77九、風險資本的退出·

82、··················································

83、···················78第九章：保險與法律事務(wù)第十章：附錄附錄一: 授權(quán)委托··························&#

84、183;···············································78附錄二：技術(shù)實施許可證&

85、#183;·················································&

86、#183;·············79附錄三：創(chuàng)業(yè)團隊簡介··································&

87、#183;································81附錄四：創(chuàng)業(yè)團隊指導(dǎo)老師···············

88、;·············································84附錄五: 產(chǎn)品包裝···

89、··················································

90、·····················85附錄六：金銀花外觀圖···························

91、········································87附錄七：選擇地優(yōu)勢········&

92、#183;·················································&

93、#183;············88附錄八: 金銀花標準操作規(guī)程（SOP）·································

94、3;············92附錄九：河南新鄉(xiāng)地圖···································

95、3;·······························95附錄十：廠址·················&#

96、183;·················································&#

97、183;·············97附錄十一：廠區(qū)平面圖··································&#

98、183;································98附錄十二：市場狀況問卷調(diào)查表··············

99、3;······································99第一章：執(zhí)行概要一、公司簡介康脂素藥業(yè)有限責任公司（以下簡稱“康脂素藥業(yè)”）是一家正在籌建中的集科研、生產(chǎn)、銷售為一體的制藥企業(yè)，公司堅

100、持 “關(guān)愛人類健康，幸福千萬家庭”的理念，為大眾做質(zhì)量好療效佳的藥品。公司利用河南大學藥學院康文藝博士的科研成果，生產(chǎn)和銷售中藥一類新藥康脂素，并逐步建立原料生產(chǎn)基地和全方位的銷售網(wǎng)絡(luò)。公司以科技為第一生產(chǎn)力，特別注重新產(chǎn)品的研發(fā)，在投資初期就計劃建立起以河南大學天然藥物研究所為依托的研發(fā)中心，并注重人才的引進及培養(yǎng)。公司廠址選在鄭州市東開發(fā)區(qū)，鄰近亞洲最大的中轉(zhuǎn)站之一鄭州火車站。該區(qū)交通便利，環(huán)境優(yōu)美，并且可以享受稅收優(yōu)惠政策。二、市場描述1、流行病學狀況1.1我國高血脂人群現(xiàn)狀2000年亞洲心血管病合作研究結(jié)果我國人群總的血脂異?；疾÷蔬_18.6%，近幾年隨著生活水平大幅度提高，血脂異常逐

101、年增加，我國血脂異?；颊呓?億人。1.2我國高血脂人群呈現(xiàn)年齡差異2004年中國 MONICA研究第二次危險因素調(diào)查，大多數(shù)地區(qū)女性的總TC水平明顯高于男性，TG水平也存在明顯的差異。1.3我國高血脂人群的分布特點血脂代謝異常在我國不同人群中具有不同的類型特征。我國人群中具有至少一項血脂異常的人群總數(shù)逾億人。1.4老年人高血脂特點2004年中國 MONICA研究，血脂異?？偦疾÷矢哌_65.9%。1.5高血脂逐漸低齡化的趨勢2004年4-10月中國 MONICA研究組織流行病學調(diào)查組,得出結(jié)論:兒童高脂血癥現(xiàn)患率明顯增高,具有地區(qū)、年齡、性別的流行病學特征。1.6高血脂和其它心血管疾病的相關(guān)性2

102、004年中國 MONICA研究得出高脂血癥為動脈粥樣硬化、冠心病等其他心血管疾病的危險因素。1.7調(diào)節(jié)高血脂藥物1.7.1西藥類：他汀類藥物包括洛伐他汀、辛伐他汀等；膽汁酸螯合劑代表有考來烯、考來替泊等；貝特類有吉非羅齊；煙酸類；抗氧化劑普羅布考；多烯脂肪酸類有 n- 3 多烯脂肪酸。1.7.2中藥類：降血清膽固醉藥物何首烏、決明、虎杖等和維生素E、黃精、黃酮類、甾體類和枯類化合物；對低密度脂蛋白代謝的影響有決明子山植及山植黃酮；對甘油三醋代謝的影響有黃連、黃琴、絞股藍、大黃、何首烏、大蒜、姜黃、銀杏葉等。；對高密度脂蛋白代謝的影響：山楂、大黃等。2產(chǎn)品競爭力：分別從產(chǎn)品療效競爭力、對比同類產(chǎn)

103、品競爭力和產(chǎn)品市場競爭力三個方面闡述產(chǎn)品競爭力。3產(chǎn)品定位產(chǎn)品適用于各種原因引起的高血脂血癥、血清膽固醇增高癥，也可用于冠心病或慢性肝炎患者的高血脂癥，動脈粥樣硬化的預(yù)防和輔助治療。公司建立以后，將針對降脂藥市場的銷售現(xiàn)狀，突出產(chǎn)品優(yōu)勢，建立售前指導(dǎo)，堅持售后服務(wù)。廣泛宣傳健康知識，提高人們的健康意識和對本產(chǎn)品的認知度、認同度，指導(dǎo)高血脂人群合理的、科學的使用本產(chǎn)品。公司初期將在鄭州、開封、洛陽設(shè)立分銷中心，采用衛(wèi)星媒體、地面促銷和及時反饋相結(jié)合的方式啟動市場，跨入大型超市、醫(yī)院藥房、藥店直銷直營，以產(chǎn)品功效吸引消費者，帶動品牌成長，再以品牌成長帶動企業(yè)發(fā)展，鞏固繼而擴大市場占有率，并積極拓展

104、廣闊的國際市場。三、公司管理公司性質(zhì)屬于有限責任制。公司實行事業(yè)部型組織機構(gòu)，面對不同的環(huán)境，按照產(chǎn)品或類別、市場用戶、地域以及不同的業(yè)務(wù)單位分別成立若干事業(yè)部，并由這些事業(yè)部進行獨立業(yè)務(wù)經(jīng)營和分權(quán)管理。由股東代表組成董事會，任命一名總經(jīng)理和兩名副總經(jīng)理，分別負責下設(shè)的財務(wù)部、營銷部、公關(guān)部（下設(shè)危機管理中心和品牌推廣部）、生產(chǎn)部、質(zhì)量管理部、研發(fā)中心和物流部八個部門。四、公司戰(zhàn)略規(guī)劃以康脂素產(chǎn)品為核心產(chǎn)品，利用技術(shù)優(yōu)勢，積極開發(fā)新產(chǎn)品，并積極申請新藥專利，保護技術(shù)成果。管理創(chuàng)新，產(chǎn)品創(chuàng)新，營銷策略創(chuàng)新，充分發(fā)揮專項技術(shù)優(yōu)勢，堅持人力資源戰(zhàn)略、企業(yè)文化戰(zhàn)略及可持續(xù)發(fā)展戰(zhàn)略。五、場地及設(shè)施 廠址

105、：址選在鄭州市東開發(fā)區(qū),位于距鄭州東貨站3公里的東三環(huán)路與航海路交叉處，鄰近亞洲最大的中轉(zhuǎn)站之一鄭州火車站。 設(shè)備包括：膠囊切割機,藥用膠囊套合機-JNG400型，NIP系列全自動膠囊充填機，脈沖氣流干燥機，溶膠罐等。六、投資與財務(wù)本公司設(shè)立在鄭州市東開發(fā)區(qū)，享受“免二減三”的稅收優(yōu)惠政策。公司成立初期共需資金1300萬元，其中吸引風險資金550萬元，河南大學注入資金500萬元，短期貸款250萬元。資金用于固定資產(chǎn)投資995萬元，流動資金305萬元。股本規(guī)模及結(jié)構(gòu)暫定為：注冊資本為1050萬元，外來風險投資入股300萬元（28.57%），河南大學專利技術(shù)入股200萬元（19.05%），資金入股

106、300萬元（28.57%），同時又引入23家風險投資共同入股250萬元（23.81%），利于籌資，化解風險，并為以后擴大規(guī)模做準備在公司的經(jīng)營過程中將獲得充分的市場信息，利用財務(wù)杠桿等財務(wù)分析工具，為公司在資金管理方面贏得優(yōu)勢。第二章：康脂素新藥研究一、產(chǎn)品來源該產(chǎn)品是由河南大學天然藥物研究所研發(fā)，經(jīng)河南大學天然藥物研究所技術(shù)轉(zhuǎn)讓，由我公司全權(quán)負責該產(chǎn)品的生產(chǎn)與經(jīng)營。并附術(shù)轉(zhuǎn)讓證書（見附錄二）。二、原料來源金銀花為忍冬科植物忍冬Lonicera japonica Thunb.、紅腺忍冬Lonicera hypoglauca Miq.、山銀花Lonicera confusa DC.或毛花柱忍冬L

107、onicera dasystyla Rehd.的干燥花蕾或帶初開的花，為中國藥典（2005年版）收載品種，可用于癰腫疔瘡，喉痹，丹毒，熱毒血痢，風熱感冒，溫病發(fā)熱，具有清熱解毒，涼散風熱之功效。本公司以河南省封丘縣金銀花種植基地為原料供應(yīng)地，其金銀花年產(chǎn)量居全國第一位，2003年該縣獲得全國惟一一家金銀花“原產(chǎn)地”認證，2005年順利通過GAP認證。三、新藥研究1臨床前研究1.1 系統(tǒng)提取分離1.1.1 金銀花的粗提取:將金銀花粉碎，用丙酮：水 1：2浸漬提取兩次，第一次7天，第二次3天，得到浸漬提取液，回收溶劑丙酮，得到丙酮部分浸膏，兩次得到的浸膏合并，濾渣在分別用相同的方法分別用甲醇和氯仿

108、提取，最后得到丙酮、甲醇和氯仿三個部分。1.1.2 金銀花的精分離：將所得到的丙酮部分的浸膏用溶劑稀釋，用硅膠、葡聚糖凝膠上柱分離，然后用合適的溶劑極性系統(tǒng)進行洗脫，經(jīng)過復(fù)雜、反復(fù)的上柱分離得到單體化合物兩個：分別記做化合物A、B。利用上述方式分別對甲醇部分和氯仿部分進行系統(tǒng)分離，甲醇部分得到一個單體化合物：記做化合物C。氯仿部分進行系統(tǒng)的分離得到三個單體化合物：分別記做化合物D、E、F。經(jīng)過系統(tǒng)分離總共從金銀花中得到六個單體化合物。1.1.3 六種化合物的結(jié)構(gòu)的測定化合物 A:黃色針狀結(jié)晶(丙酮) ,熔點200201。易溶于丙酮、甲醇、乙酸乙酯。溴酚藍和三氯化鐵-鐵氰化鉀反應(yīng)均為陽性,推測其

109、為酚酸性物質(zhì)。UVmax(MeOH,nm): 207，258，294；IR(KBr,cm ) : 3410，2925，2856，1655，1603, 1527，1455，1382，1289，1 247，939，879，823，765，638，555；1H-NMR(400 MHz，Acetone ) :7.51(1H ,d ,J =2.0 Hz ,H-22)，7.46(1H, dd, J = 8.2Hz，2.0 Hz，H-26)，6.88(1H, d, J =8.2 Hz, H-25)；13C-NMR(100 MHz，Acetone)：122. 8(C-21)，117. 2(C-22)，145.

110、 4(C-23)，150. 6(C-24)，115. 5(C-5)，123.4(C-26)，167.6(COOH)?；衔顱:黃色結(jié)晶(丙酮) ,熔點172174。易溶于丙酮、甲醇.溴酚藍和三氯化鐵 -鐵氰化鉀反應(yīng)均為陽性,推測其為酚酸性物質(zhì)。IR(KBr ,cm ) :3484 ,3310 ,2965 ,2840 ,1 679,1604,1532,1443,1367,1306,1279,1246,1188,1109,1045,974,933 ,856；H2NMR(400 MHz ,Acetone2D6 +D2 O):7.02(1H ,2d ,J =2.0 Hz ,H22) ,6.88(1H

111、,dd ,J= 8.3Hz ,1.9 Hz ,H26) ,6.78(1H ,d ,J = 8.0 Hz,H25) ,7.47(1H2 13d,J=16.0 Hz ,H27),6. 16(1H,d ,J =16.0Hz ,H28) ,3. 66(3H,s,- OCH3 ) ；C2NMR(Acetone2D6 +2D2 O):127.9(C21),111.8(C22),149.3(C23),150.3(C24),116.5(C25),123.8(C26),146.5(C27116.1(C28),170.8( - COOH)。故鑒定該化合物為結(jié)構(gòu)為B。化合物C:白色粉末(甲醇),熔點199201。易

112、溶于甲醇、水。溴酚藍反應(yīng)為陽性,推測其為有機酸類化合物。IR( KBr ,cm ) :3415,3113,2936 ,1717,1670,1451,1417,1 235,1157,999,854,763,543,1496；H2NMR(400 MHz,D2O):5.67(1H,d,J=7.6Hz,H22),7.40(1H,d,J=7.6Hz,H23) ,3.53(2H ,13q,J=6.8Hz,7.2Hz , -O-CH2 - ),1.05(3H ,t ,J =6.8 Hz ,- CH3)；C2NMR(400 MHz ,D2 O) :167.4( - COOH) ,143.3(C22) ,100

113、.9(C23) ,57.3(-O-CH2- ) ,16.7( - CH3 )。故鑒定該化合物結(jié)構(gòu)為C。化合物D:白色固體(氯仿),熔點7072。易溶于氯仿,H2NMR(400 MHz,CDCl3 ) :139(3H ,t ,J=6.8Hz) ,1. 25(66H) ,3. 65(2H ,t ,J = 6.8Hz)；C2NMR(400 MHz,CDCl3):63.1,-18,31.9,29.7,29.6,25.7,22.7,14.1IR( KBr,cm ):3 395,2919,2850,1738,1613,1467,5,1372,1275,1060,723。故鑒定該化合物結(jié)構(gòu)為D?；衔顴:白

114、色固體(氯仿),熔點5456。易溶于氯仿、乙酸乙酯。H2NMR(400 MHz,CDCl3):9(3H ,t ,J =6.8Hz),1.25(42H),1.54(4H) ,3.77(2H ,t ,J = 6.8 Hz)。故鑒定該化合物結(jié)構(gòu)為E。化合物 F:黃色固體(氯仿) ,熔點4042。易溶于氯仿、乙酸乙酯H2NMR(400 MHz ,CDCl3 ) :1(1H ,s ,- CHO) ,7.22(1H ,d ,J =2.8Hz),6.52(1H ,d ,J =3.2 Hz) ,4.7(2H,s,H22),1.25(3H,CH3)。故鑒定該化合物結(jié)構(gòu)為F。1.2 體外實驗研究1.2.1試驗方法

115、及原理（1）DPPH方法及原理DPPH法是20世紀50年代提出來的，最初用于發(fā)現(xiàn)食品中的供氫體，后來廣泛用于定量測定酚類物質(zhì)、黃酮類物質(zhì)、香辛料類、食品、水果和揮發(fā)油等的抗氧化能力。DPPH(二苯代苦味?；杂苫?是一種很穩(wěn)定的以氮為中心的自由基（見圖1），其孤對電子在515nm附近有強吸收（其乙醇水溶液顯深紫色）。當有供氫能力的抗氧化劑存在時，孤對電子被配對，吸收消失或減弱，而吸光度變小的程度與自由基被清除的程度呈定量關(guān)系，因而可用分光光度法進行定量分析。 圖1 DPPH結(jié)構(gòu)及其還原產(chǎn)物Fig.1 Structure of DPPH and its reduction by the anti

116、oxidant RH（2）ABTS方法及原理 ABTS是一種水溶性的自由基引發(fā)劑，該方法就是以此為顯色劑，經(jīng)活性氧氧化后生成穩(wěn)定的藍綠色陽離子自由基ABTS+，向其中加入被測物質(zhì)，當待測物質(zhì)中含有抗氧化物時，該物質(zhì)會與ABTS+發(fā)生發(fā)應(yīng)而使反應(yīng)體系顏色褪去，結(jié)構(gòu)式如圖2所示。在ABTS+的最大吸收波長（一般選擇734 nm）處檢測吸光度的變化。檢測結(jié)果與以Trolox（6-Hydroxy-2,5,7,8-tetram ethylchroman-2-carboxylic acid ，即 6-羥基-2,5,7,8-四甲基苯并二氫吡喃-2羧酸），一種合成的類似于VE的水溶性物質(zhì)的對照標準體系比較，換

117、算出被測物質(zhì)總的抗氧化能力，結(jié)果多表示為達到一定濃度測試物質(zhì)相當?shù)目寡趸芰λ枰腡rolox的濃度。 圖2 ABTS及其自由基結(jié)構(gòu)Fig.2 Structure of ABTS and its free radical（3）FRAP方法及原理FRAP方法的原理：在低pH值的溶液中，F(xiàn)e3+-三吡啶三啞嗪（tripyridyl-triazine，TPTZ）可被抗氧化劑還原為二價鐵形式，呈現(xiàn)出明顯的藍色，并在593 nm處有最大吸收，根據(jù)吸光度的大小計算出抗氧化活性的強弱。結(jié)果以Fe2+當量或相對于標準抗氧化劑的能力來表示。1.2.2操作方法（1）DPPH方法將樣品用甲醇配制成一系列濃度，取0

118、.1 ml樣品加入3.5 ml DPPH甲醇溶液（0.06 mmol/L），混勻，30 min后測定515 nm處吸光度；同法0.1 ml甲醇+ 3.5 ml DPPH溶液混勻測定吸光度。每份樣品平行操作3次，取平均值。按照以下公式計算自由基清除率： DPPH radical scavenging rate(%) = （Acontrol-Asample）/Acontrol×100式中，Acontrol為DPPH本身在測定波長的吸收，Asample為樣品對DPPH作用后的吸收度數(shù)值（除去樣品自身吸收）。（2）ABTS方法將樣品用甲醇配制成一系列濃度，取0.15 ml樣品加入2.85 m

119、l ABTS自由基工作液，混勻，10 min后測定734 nm處吸光度；同法0.15 ml甲醇 + 2.85 ml ABTS自由基工作液混勻測定吸光度。每份樣品平行操作3次，取平均值。按照以下公式計算自由基清除率： ABTS radical scavenging rate(%) = （Acontrol-Asample）/Acontrol×100式中，Acontrol為ABTS本身在測定波長的吸收，Asample為樣品對ABTS作用后的吸收度數(shù)值（除去樣品自身吸收）。 （3）FRAP方法將樣品用甲醇配制成一系列濃度，取0.2 ml樣品加入3.8 ml新鮮配制的TPTZ工作液，混勻，37

120、反應(yīng)30 min后測定593 nm處吸光度。每份樣品平行操作3次，取平均值。若所測定樣品吸光度值超過線性范圍，則需要進一步稀釋樣品。1.2.3試驗結(jié)果1.2.3.1 DPPH實驗結(jié)果見表1和表2 由表2可知，化合物DPPH法抗氧化活性由大到小依次是C > D > E > F > A > B >LGL表1 陽性對照品清除DPPH自由基的半數(shù)抑制濃度樣本數(shù)(N)終濃度（µg/ml）A 值(X±SD)抑制率（%）IC50（µg/ml）PG3-0.578±0.002-0.8632.780.028±0.00295.21

121、31.670.087±0.00384.8830.830.295±0.01448.9330.420.425±0.00726.4330.210.505±0.00712.52BHA3-0.575±0.001-3.43316.670.034±0.00194.0938.330.080±0.00386.1534.170.233±0.00659.5932.080.397±0.00630.8431.040.472±0.00317.83BHT3-0.584±0.001-18.793111.110.045

122、±0.00292.29383.330.065±0.00288.81333.330.204±0.00465.15316.670.343±0.01741.1238.330.428±0.00726.52注：“N”為樣本數(shù)表2 化合物清除DPPH自由基的半數(shù)抑制濃度No.樣本數(shù)(N)終濃度（µg/ml）A 值(X±SD)抑制率（%）IC50（µg/ml）A3-0.593±0.002-32.863111.110.034±0.00194.32383.330.039±0.00093.42355.56

123、0.129±0.00178.28313.890.456±0.00522.8936.940.521±0.00311.89B3-0.586±0.002-42.2135.550.022±0.00296.2532.780.070±0.00288.0531.390.257±0.00056.1430.690.411±0.00929.8630.350.493±0.00215.87C3-0.586±0.002-1.1335.550.022±0.00296.2532.780.070±0.002

124、88.0531.390.257±0.00056.1430.690.411±0.00929.8630.350.493±0.00215.87D3-0.544±0.003-14.33355.560.161±0.01670.4316.670.235±0.00556.838.330.371±0.00331.834.170.384±0.00631.062.080.521±0.0036.46E30.616±0.003-20.06355.560.040±0.00293.45327.780.219

125、77;0.00564.50313.890.405±0.00234.3136.940.502±0.00417.1633.470.553±0.0098.75F30.594±0.00224.61383.330.032±0.00194.56355.560.062±0.00389.62327.780.271±0.00154.40313.890.403±0.00432.3836.940.495±0.00617.00LGL3-0.593±0.002-59.43111.110.034±0.00194.

126、32383.330.039±0.00080.42355.560.129±0.00148.28313.890.456±0.00522.8936.940.521±0.00311.891.2.3.2 ABTS實驗結(jié)果由表2可知，化合物ABTS法抗氧化活性由大到小依次是C > E > B > F > D > A > LGL圖3 Trolox清除ABTS自由基標準曲線表4 陽性對照品清除ABTS自由基的半數(shù)抑制濃度（N=3）No.終濃度（µg/ml）A 值(X±SD)抑制率（%）IC50（µg/ml

127、）RACT50µmol/gPG-0.764±0.007-0.6615509.091.50.036±0.00195.291.250.169±0.00577.880.6250.434±0.00643.190.31250.580±0.00424.080.156250.655±0.00414.27BHA-0.758±0.006-1.725951.1650.001±0.00199.873.750.015±0.00498.022.50.271±0.00662.251.250.452±0.

128、00440.370.6250.599±0.00720.98BHT-0.758±0.008-6.041696.11250.094±0.00287.612.50.229±0.00469.796.250.375±0.00250.533.1250.512±0.00732.451.56250.605±0.01520.18表5 化合物清除ABTS自由基的半數(shù)抑制濃度（N=3）No.終濃度（µg/ml）A 值(X±SD)抑制率（%）IC50（µg/ml）RACT5µmol/gA-0.783±0.006-4.822125.8612.50.067±0.00391.449.3750.118±0.00184.936.250.274±0.00565.013.1250.480±0.00538.7B-0.837±0.007-3.582859.22250.063